Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
This report contains market size and forecasts of Biosimilar Drug in global, including the following market information:
Global Biosimilar Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Biosimilar Drug Market Sales, 2017-2022, 2023-2028, (K Dose)
Global top five Biosimilar Drug companies in 2021 (%)
The global Biosimilar Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Biosimilar Drug include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, Henlius, Amgen, Eli Lilly, Sandoz, Changchun High Tech and Innovent. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biosimilar Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilar Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Dose)
Global Biosimilar Drug Market Segment Percentages, by Type, 2021 (%)
Injection
Tablets
Other Types
Global Biosimilar Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Dose)
Global Biosimilar Drug Market Segment Percentages, by Application, 2021 (%)
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Global Biosimilar Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Dose)
Global Biosimilar Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilar Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Biosimilar Drug revenues share in global market, 2021 (%)
Key companies Biosimilar Drug sales in global market, 2017-2022 (Estimated), (K Dose)
Key companies Biosimilar Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent